
|Videos|September 21, 2016
Were PCSK9 Inhibitors Overhyped?
Author(s)Lauren Santye, Assistant Editor
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.
Advertisement
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Long COVID and Brain Health
2
Expert: Why Cutting Alcohol May Enhance GLP-1 Outcomes in Patients With Obesity and Diabetes Risk
3
Depression May Be an Early Manifestation of Neurodegenerative Changes Leading to Movement Disorders
4
Recapping 2025 ASHP Midyear: Expanding the Pharmacist’s Role in Patient Care, Technology, and Health System Resilience
5
















